Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01558310
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:35:17.645654+00:00
Published At
2012-07-18T00:00:00+00:00
Record Updated At
2012-07-18
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Scalp Psoriasis", "Plaque Psoriasis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2012-07-18"
protocolSection.identificationModule.nctId
"NCT01558310"
protocolSection.identificationModule.officialTitle
"A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara \u2122 (Ustekinumab) in The Treatment of Scalp Psoriasis"
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Scalp Psoriasis (protocolSection.conditionsModule.conditions)
  • Plaque Psoriasis (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.